Zidi Sabrina, Sghaier Ikram, Zouidi Ferjeni, Benahmed Amira, Stayoussef Mouna, Kochkar Radhia, Gazouani Ezzedine, Mezlini Amel, Yacoubi-Loueslati Besma
Faculty of Sciences of Tunis, Laboratory of Micro-Organisms and Active Biomolecules, El Manar University, 2092 El MANAR I, Tunis, 1092, Tunisia,
Pathol Oncol Res. 2015 Sep;21(4):1101-7. doi: 10.1007/s12253-015-9941-8. Epub 2015 Apr 30.
Our study aimed to evaluate the association between IL-1α (4845 G/T), IL-1β (-511C/T) and IL-1RN (VNTR) polymorphisms and risk of cervical cancer. This case-control study investigates three polymorphisms in 130 patients and 260 controls by PCR-restriction fragment length polymorphism (RFLP). The IL-1RN (VNTR) A1/A3 genotype appear as a cervical cancer risk factor (p = 0.048; OR = 2.92; 95 % CI = 1.00-8.74), moreover, the L/2* decreased the risk (p = 0.011; OR = 0.47; 95 % CI = 0.25-0.88) and may be a protective factor against this pathology. Stratified analysis according to the FIGO stage subgroup revealed that the IL-1β-511 T/T genotype and T allele may be a protective factors against cervical cancer development for patients with early stage (p = 0.030; OR = 0.46; 95 % CI = 0.22-0.96) (p = 0.020; OR = 0.68; 95 % CI = 0.48-0.97). However, for the patients with advanced FIGO stage, IL-1RN-VNTR L/2* genotype appear as a protective factor for this pathology (p = 0.023; OR = 0.29; 95 % CI = 0.08-0.99). The (G-T-L) haplotype showed a significant decreased frequency in cervical cancer patients as compared to controls (p = 0.032; OR = 0.53; 95 % CI = 0.29-0.95). In contrast, the (T-T-2*) combination appear a risk factor for the development of cervical cancer (p = 0.018; OR = 1.57; 95 % CI = 1.07-2.30). Our study suggested that IL1 cluster polymorphisms and haplotypes may be a genetic risk factor for cervical cancer.
我们的研究旨在评估白细胞介素-1α（4845 G/T）、白细胞介素-1β（-511C/T）和白细胞介素-1受体拮抗剂（IL-1RN）基因多态性与宫颈癌风险之间的关联。这项病例对照研究通过聚合酶链反应-限制性片段长度多态性（PCR-RFLP）检测了130例患者和260例对照中的三种多态性。白细胞介素-1受体拮抗剂（IL-1RN）的A1/A3基因型表现为宫颈癌的一个风险因素（p = 0.048；比值比[OR]=2.92；95%置信区间[CI]=1.00-8.74），此外，L/2降低了风险（p = 0.011；OR = 0.47；95%CI = 0.25-0.88），可能是针对这种病理情况的一个保护因素。根据国际妇产科联盟（FIGO）分期亚组进行的分层分析显示，白细胞介素-1β-511 T/T基因型和T等位基因可能是早期患者预防宫颈癌发生的保护因素（p = 0.030；OR = 0.46；95%CI = 0.22-0.96）（p = 0.020；OR = 0.68；95%CI = 0.48-0.97）。然而，对于FIGO晚期患者，白细胞介素-1受体拮抗剂-可变数目串联重复序列（IL-1RN-VNTR）L/2基因型表现为针对这种病理情况的一个保护因素（p = 0.023；OR = 0.29；95%CI = 0.08-0.99）。与对照组相比，（G-T-L）单倍型在宫颈癌患者中的频率显著降低（p = 0.032；OR = 0.53；95%CI = 0.29-0.95）。相反，（T-T-2*）组合表现为宫颈癌发生的一个风险因素（p = 0.018；OR = 1.57；95%CI = 1.07-2.30）。我们的研究表明，白细胞介素-1基因簇多态性和单倍型可能是宫颈癌的一个遗传风险因素。
